Proton beam therapy versus radiofrequency ablation for patients with treatment-na ïve single hepatocellular carcinoma: a propensity score analysis
Conclusion: After propensity score matching, PBT showed no significant difference in RFS and OS compared to RFA. PBT can be an alternative for patients with solitary treatment-naïve HCC. (Source: Liver Cancer)
Source: Liver Cancer - December 6, 2022 Category: Cancer & Oncology Source Type: research
Imaging Diagnosis of various HCC subtypes and Its Hypervascular Mimics: Differential Diagnosis Based on Conventional Interpretation and Artificial Intelligence
Background. Hepatocellular carcinoma (HCC) is unique among malignancies, and its characteristics on contrast imaging modalities allow for a highly accurate diagnosis. The radiological differentiation of focal liver lesions is playing an increasingly important role, and the Liver Imaging Reporting and Data System (LI-RADS) adopts a combination of major features including arterial phase hyperenhancement (APHE) and washout pattern. Summary. Specific HCCs such as well or poorly differentiated type, subtypes including fibrolamellar or sarcomatoid and combined hepatocellular-cholangiocarcinoma does not often demonstrate APHE and...
Source: Liver Cancer - December 6, 2022 Category: Cancer & Oncology Source Type: research
Trends and Disparities in Stage-specific Incidence of Hepatocellular Carcinoma among US Adults, 2004-2019
Conclusions: Disparities in incidence trends may reflect the inequalities in access to primary health care. More efforts are still in great demand for the vulnerable population. (Source: Liver Cancer)
Source: Liver Cancer - December 5, 2022 Category: Cancer & Oncology Source Type: research
Contents Vol. 11, 2022
Liver Cancer 2022;11:I –VIII (Source: Liver Cancer)
Source: Liver Cancer - December 2, 2022 Category: Cancer & Oncology Source Type: research
Acknowledgement to Reviewers
Liver Cancer 2022;11:583 –584 (Source: Liver Cancer)
Source: Liver Cancer - December 2, 2022 Category: Cancer & Oncology Source Type: research
APPLE News
Liver Cancer 2022;11:582 –582 (Source: Liver Cancer)
Source: Liver Cancer - December 2, 2022 Category: Cancer & Oncology Source Type: research
Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study
Conclusion. First-line combination of TACE, lenvatinib, and anti-PD-1 antibodies prov ides a better chance of conversion therapy in patients with initially uHCC. Furthermore, salvage surgery after conversion therapy is effective and safe and has the potential to provide excellent long-term survival benefits. (Source: Liver Cancer)
Source: Liver Cancer - November 30, 2022 Category: Cancer & Oncology Source Type: research
